Clin2
NCT06665880Worth exploringNot yet recruiting

Genes and proteins in hard-to-treat epilepsy patients

Drug Resistant EpilepsyTraumatic Brain Injury Without Open Intracranial Wound

Part of Brain & nervous system, Injuries & trauma clinical trials.

This study looks at genes, proteins, and other body chemicals in people with drug-resistant epilepsy (seizures that continue despite trying multiple medications). By studying samples from people who are already having SEEG surgery to find where seizures start, researchers hope to discover new clues about what makes epilepsy hard to treat. The results may help develop better tests or treatments in the future.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
16 people
Ages
14 years to 60 years
Study type
Observational

Who can take part

  • You must be between 14 and 60 years old and of Han Chinese ethnic background.
  • You must have drug-resistant epilepsy — meaning your seizures have continued despite trying at least two appropriate seizure medications.
  • You must be scheduled for a procedure called SEEG (stereoelectroencephalography), where fine wires are placed in the brain to find where your seizures start.
  • You cannot have a progressive brain disease such as a degenerative disorder or a growing brain tumor.
  • You must not have significant heart, liver, or kidney disease, severe side effects from your current seizure medications, significant intellectual disability, or a history of alcohol or drug abuse.
  • You must be able to undergo MRI safely — this means no pacemaker, metal implants, or severe claustrophobia that prevents an MRI.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06557720Recruiting
Imaging study for hard-to-control epilepsy

This study looks at how different brain scans (like MRI, PET, and EEG) can help find the exact spot where seizures start in people whose epilepsy hasn't been controlled by medicines. It aims to better understand drug-resistant epilepsy so doctors can plan more accurate treatments.

Xi'an
NCT06059157Recruiting
Brain mapping with advanced MRI for epilepsy surgery

This trial uses special MRI scans to create a detailed map of the brain areas causing seizures, helping doctors plan SEEG surgery. It's for people with hard-to-control epilepsy who are already scheduled for SEEG.

Brussels
NCT07399327Recruiting
SEEG thermocoagulation for hard-to-treat epilepsy

This study is looking at how well a procedure called SEEG thermocoagulation (a way to stop seizures by heating a small area of brain tissue) works for people with epilepsy that doesn't improve with medication. By joining, you will help doctors understand why this treatment works for some people and not others.

Marseille
NCT07305311Not yet recruiting
Brain stimulation for drug-resistant epilepsy

This study looks at how a specific part of the brain (the piriform cortex) affects seizure activity. It uses SEEG, a way to record brain signals from inside the brain, to test how stimulating this area can help control seizures, which might lead to better treatments for epilepsy.

Beijing, Beijing Municipality
NCT02890641Recruiting
Study of brain signals and genes in hard-to-treat epilepsy

This study looks at genetic factors and brain electrical activity in children whose seizures are difficult to control with standard medicines. It also involves exams like MRI and possibly procedures under anesthesia, to better understand seizure causes and help future care.

Paris
NCT07014592Recruiting
Brain activity study in drug-resistant epilepsy patients

This study looks at brain activity in people with epilepsy that does not get better with medicine. Researchers want to record your brain's electrical responses during surgery for your seizures to learn more about how epilepsy works.

Ann Arbor, Michigan

Hear when a new Drug Resistant Epilepsy trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.